We are committed to improving population health
We are committed to improving population health
Our Mission, Vision and Strategy
Our Mission is to improve population health by inventing and developing innovative therapies and vaccines, through broad in-house capabilities and creative collaborations, to help address important unmet needs.
Our Vision is to be a leader in providing novel drug therapies and vaccines to improve population health around the world.
Our Strategy is to use our integrated development engine to advance innovative programs across multiple therapeutic areas into the clinic while maximizing asset potential.
To learn more About Us, view our video.
Latest News
About Tonix Pharmaceuticals
Tonix has a robust pipeline of programs in development stages ranging from preclinical to mid-Phase 3, across multiple therapeutic modalities, employing varied routes of administration. Tonix’s pipeline is managed by a team of passionate professionals that are adept at advancing innovative programs into the clinic.
While many of Tonix’s product candidates are proprietary, in-house developments, it also has collaborations with world-class academic and non-profit research organizations as well as license agreements with other biotech companies.
Therapeutic Areas
Central Nervous System
Tonix is dedicated to finding cures for difficult to treat, widely occurring, chronic disorders of the central nervous system including pain, neurological, psychiatric and addiction conditions.* Our goal is to heal sufferings of millions through scientific advancements.
Immunology
We are advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.*
Infectious Disease
Tonix’s infectious disease portfolio targets pathogenic infections, including the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines, antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to combat infections like SARS-CoV-2.
Rare Disease
Tonix is committed to improving patient care, including for those suffering from rare diseases and for which no drug has been approved. Rare diseases are often caused by genetic disorders and are characterized by complex symptoms. A rare disease is a condition that affects fewer than 200,000 people in the US as defined in the Orphan Drug Act of 1983.
Central Nervous System
Tonix is dedicated to finding cures for difficult to treat, widely occurring, chronic disorders of the central nervous system including pain, neurological, psychiatric and addiction conditions.* Our goal is to heal sufferings of millions through scientific advancements.
Immunology
We are advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.*
Infectious Disease
Tonix’s infectious disease portfolio targets pathogenic infections, including the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines, antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to combat infections like SARS-CoV-2.
Rare Disease
Tonix is committed to improving patient care, including for those suffering from rare diseases and for which no drug has been approved. Rare diseases are often caused by genetic disorders and are characterized by complex symptoms. A rare disease is a condition that affects fewer than 200,000 people in the US as defined in the Orphan Drug Act of 1983.
Pipeline Highlights
Using our integrated clinical development engine, we advance innovative programs into the clinic while maximizing asset potential.
Preclinical
Phase I
Phase II
Phase III
TNX-102 SL Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrolling
Mid-Phase III
TNX-1300 Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation
Mid-Phase II
TNX-1850 COVID-19 Vaccine
Phase I start — targeting 2H 2023
Preclinical
TNX-1500 Organ Transplant Rejection / Autoimmune Disorders
Phase I start — targeting 1H 2023
Preclinical
Management Team
“Many frontiers remain in the fields of medical science and drug development. At Tonix, we have carefully chosen pursuits in immunology, rare diseases, infectious diseases, and central nervous system disorders. We are building capabilities in synthetic biology, precision medicine, protein engineering, and vaccine manufacturing to develop better and safer medicines. Our ultimate goals are to improve and extend the lives of millions of people and, importantly, to reward the dedication and commitment of our stakeholders.”
— Dr. Seth Lederman, M.D., President and CEO, Tonix Pharmaceuticals